Zentalis Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Azenosertib is advancing in platinum-resistant ovarian cancer with ongoing DENALI and ASPENOVA trials, targeting cyclin E1-positive patients and aiming for accelerated and full approval. The MIRROR study will explore earlier-line combinations, while regulatory and operational milestones are on track.
-
Azenosertib is advancing in late-stage trials for PROC patients with high Cyclin E1 expression, targeting a 21,500-patient market in the US, EU4, and UK. The DENALI and ASPENOVA trials are on track, with consistent efficacy, manageable safety, and regulatory alignment for accelerated approval.
-
Leadership is advancing azenosertib as a first oral, non-chemo option for PROC, with pivotal DENALI and ASPENOVA trials underway. The drug targets Cyclin E1 positive patients, offering improved quality of life and manageable safety, with regulatory alignment for accelerated and full approval.
-
Azenosertib is advancing through pivotal trials for platinum-resistant ovarian cancer with high cyclin E1, using a biomarker-driven approach and adaptive trial designs to accelerate approval. The drug shows a favorable safety profile and differentiation from existing therapies, with future plans for combinations and potential expansion into other indications.
Fiscal Year 2025
-
Azenosertib demonstrates strong efficacy and safety in Cyclin E1-positive PROC, with a phase two trial underway and a phase three confirmatory study planned for 2026. The companion diagnostic is ready, and robust site activation supports global enrollment.
-
Azenosertib is advancing as a differentiated, oral therapy for platinum-resistant ovarian cancer, with strong response rates and a favorable safety profile. The DENALI trial is on track for top-line data by end of 2026, and combination strategies are being explored for broader impact.
-
Azenosertib is being advanced in platinum-resistant ovarian cancer with a focus on cyclin E1 biomarker selection, showing promising response rates and durability. The Denali trial is on track for accelerated approval, with FDA alignment and a strong cash position supporting development through late 2027.
-
Azenosertib demonstrates strong efficacy and tolerability in cyclin E1 positive platinum-resistant ovarian cancer, with a registration trial underway and top-line data expected by late 2026. The company is well-funded through 2027 and plans to expand into additional indications if successful.
-
Azenasertib is advancing as a first-in-class, non-chemo oral therapy for cyclin E1 overexpressing, platinum-resistant ovarian cancer, with a focus on accelerated approval and strong market potential. Ongoing trials compare 300mg and 400mg doses, with top-line data expected by end of 2026.
-
Azenosertib, a WEE1 inhibitor, is advancing in late-stage trials for Cyclin E1-positive PROC, targeting a significant unmet need with a biomarker-driven approach. Robust clinical data show over 30% response rates and manageable safety, with top-line phase 2 data expected by end of 2026. Expansion into other tumor types is being explored, but the primary focus remains on PROC.
-
Azenosertib shows strong efficacy and safety in Cyclin E1-positive PROC, with ongoing pivotal trials and a large addressable market. Top-line data from the DENALI Part 2 trial is expected by end of 2026, and the company is well-funded to pursue further indications.
-
Azenosertib is advancing in registration trials for platinum-resistant ovarian cancer, focusing on cyclin E1-positive patients with a strong efficacy and safety profile. Top-line data is expected by late 2026, with a companion diagnostic in development and additional studies exploring broader indications.
-
Azenosertib is advancing in platinum-resistant ovarian cancer, focusing on cyclin E1 positive patients, with strong clinical data and a clear regulatory path for accelerated approval. The Denali trial is central, with top-line data expected by end of 2026 and a confirmatory phase three to follow.
-
Azenosertib shows >30% response rates and a favorable safety profile in Cyclin E1 positive PROC patients, with a seamless FDA-aligned trial design supporting accelerated approval. Operational improvements and a strong financial position enable rapid execution, with key data updates expected in 2026.
-
Azenosertib showed consistent response rates above 30% in cyclin E1 positive PROC patients, with durable responses and a favorable safety profile at 400 mg. FDA alignment enables a seamless trial design for accelerated approval, and improved patient selection and supportive care are expected to enhance outcomes.
Fiscal Year 2024
-
A partial FDA clinical hold was placed on azenosertib monotherapy studies after two sepsis-related deaths, pausing new enrollment but allowing ongoing treatment. Key data from fully enrolled studies, including biomarker-driven analyses, will be disclosed in 2024.